Vytorin expert panel says 'go back to statins'

"We were very disappointed in the ACC panel. We had expected a balanced discussion and we really didn't think the panel today served patients well," Dr. Robert Spiegel, chief medical officer of Schering-Plough told Reuters.

"We were particularly concerned because we know of no safety concerns that should be raised after the Enhance trial. But we do know a lot about the value of LDL-lowering and that is what we had hoped the scientific discussion would address," Spiegel said. (Additional reporting by Debra Sherman; Editing by Tom Hals)